Molbio Diagnostics IPO
Upcoming MainboardAlready have an account? Apply now
Molbio Diagnostics IPO details
Schedule of Molbio Diagnostics
| Issue open date | 10 Aug 2026 |
| Issue close date | 12 Aug 2026 |
| UPI mandate deadline | 12 Aug 2026 (5 PM) |
| Allotment finalization | 13 Aug 2026 |
| Refund initiation | 14 Aug 2026 |
| Share credit | 14 Aug 2026 |
| Listing date | 17 Aug 2026 |
| Mandate end date | 27 Aug 2026 |
| Lock-in end date for anchor investors (50%) | 11 Sep 2026 |
| Lock-in end date for anchor investors (remaining) | 10 Nov 2026 |
Note: The schedule is tentative. The anchor lock-in period ends 30 days after the actual allotment date for 50% of the shares and 90 days after for the remaining portion. The allotment status can be checked on the registrar's website and the exchange website.
About Molbio Diagnostics
Molbio Diagnostics is a point-of-care diagnostics company that develops and manufactures healthcare technologies for diagnosing infectious and non-communicable diseases. The company’s core business revolves around its proprietary ‘Truenat’ platform, a portable, battery-operated polymerase chain reaction (PCR) system designed for use in resource-limited settings. This platform provides rapid and accurate test results within approximately one hour. The company’s primary source of revenue is the sale of its ‘Truenat’ devices and the recurring sale of compatible, disease-specific micro-PCR test kits. Molbio offers a wide range of tests for various infectious diseases, including tuberculosis, COVID-19, Hepatitis B and C, HIV, and HPV. Through its subsidiaries, the company also provides devices related to radiology and digital pathology.
Financials of Molbio Diagnostics
Issue size
| Funds Raised in the IPO | Amount |
| Total issue size | 939.70 |
| Fresh Issue – Proceeds go to the company | 200 |
| Offer for sale – Proceeds go to the existing investors | 739.70 |
Utilisation of proceeds
| Purpose | INR crores (%) |
| R&D facility, Centre of Excellence and office infrastructure | 105.5 (52.75%) |
| Plant, machinery and equipment for manufacturing units | 72.2 (36.10%) |
| General corporate purposes | 22.3 (11.15%) |
Strengths
- Proprietary TruNAT platform enables rapid, point-of-care molecular diagnostics.
- Strong footprint in government and public health procurement programs.
- Wide disease coverage including TB, COVID-19, HIV, hepatitis and HPV.
- In-house R&D supported by integrated manufacturing capabilities.
- Global presence with products deployed across multiple countries.
Risks
- Heavy dependence on government and international aid agency funding.
- High revenue concentration from tuberculosis-related test kits.
- A limited number of large customers contribute a significant share of revenues.
- Regulatory delays may impact the commercialisation of new diagnostic tests.
- Demand fluctuations are linked to public health policies and funding cycles.